Paragraph 6002 Class E airspace areas designated as a surface area for an airport.

* * * * *

AGL MN E2 Mankato, MN [Revised]

Mankato Municipal Airport, MN
(Lat. 44°13′18″ N, long. 93°55′08″ W)
Mankato VOR/DME
(Lat. 44°13′12″ N, long. 93°54′44″ W)

Within a 4.1-mile radius of Mankato Municipal Airport and within 1.8 miles each side of the Mankato VOR/DME 167° radial, extending from the 4.1-mile radius to 7.0 miles south of the VOR/DME, and within 2.7 miles each side of the Mankato VOR/DME 326° radial, extending from the 4.1–mile radius to 7.0 miles northwest of the VOR/DME. This Class E airspace is effective during the specific dates and times established in advance by a Notice to Airmen.The effective date and time will thereafter be continuously published in the Airport/Facility Directory.

* * * * *

Paragraph 6005 Class E airspace areas extending upward from 700 feet or more above the surface of the earth

* * * * *

AGL MN E5 Mankato, MN [Revised]

Mankato Municipal Airport, MN
(Lat. 44°13′18″ N, long. 93°55′08″ W)

That airspace extending upward from 700 feet above the surface within a 7.0-mile radius of Mankato Municipal Airport and within 2.0 miles each side of the 047° bearing from the airport, extending from the 7.0-mile radius to 8.0 miles northeast of the airport.

* * * * *

Issued in Des Plaines, Illinois on December 15, 1997.

Maureen Woods,

Manager, Air Traffic Division.

[FR Doc. 98–2448 Filed 1–30–98; 8:45 am]

BILLING CODE 4910–13–M

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Airspace Docket No. 97–ANM–9]

Modifications of the Legal Descriptions of Federal Airways in the Vicinity of Colorado Springs, CO

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule; delay of effective date.

SUMMARY: This action delays the effective date for the modifications to the legal descriptions of Federal Airways V–19, V–81, V–83, and V–108 until April 23, 1998. The FAA is taking this action due to a requirement for additional coordination with internal offices of the FAA.

DATES: The effective date of 0901 UTC, February 26, 1998, is delayed until 0901 UTC, April 23, 1998.

FOR FURTHER INFORMATION CONTACT: Ken McElroy, Airspace and Rules Division, ATA–400, Office of Air Traffic Airspace Management, Federal Aviation Administration, 800 Independence Avenue, SW., Washington, DC 20591; telephone: (202) 267–8783.

SUPPLEMENTARY INFORMATION: Airspace Docket No. 97–ANM–9, published in the **Federal Register** on December 12, 1997 (62 FR 65358), modified the legal descriptions of Federal Airways V–19, V–81, V–83, and V–108 by replacing the name ''Colorado Springs'' VORTAC with ''Black Forest'' VORTAC. The effective date of this change is delayed until April 23, 1998.

The FAA has determined that this regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. Therefore, this regulation: (1) Is not a significant regulatory action under Executive Order 12866; (2) is not a ''significant rule'' under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a Regulatory Evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this rule will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

Delay of Effective Date

The effective date of the final rule, Airspace Docket No. 97–ANM–9, as published in the **Federal Register** on December 12, 1997 (62 FR 65358), is hereby delayed until 0901 UTC, April 23, 1998.

Authority: 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959–1963 Comp., p. 389.

Issued in Washington, DC, on January 22, 1998.

Reginald C. Matthews,

Acting Program Director for Air Traffic Airspace Management.

[FR Doc. 98–2447 Filed 1–30–98; 8:45 am]

BILLING CODE 4910–13–P

COMMODITY FUTURES TRADING COMMISSION

17 CFR Part 11

Delegation of Authority to Conduct Investigations in Assistance of Foreign Futures Authorities; Correction

AGENCY: Commodity Futures Trading Commission.

ACTION: Final rules; correction.

SUMMARY: On April 11, 1997, the Commission published in the **Federal Register** (62 FR 17702) final rules amending certain provisions of the Commission's Rules to formalize the authority of the Director of the Division of Enforcement to conduct investigations in assistance of foreign futures authorities. The purpose of the amendments was to add language to the existing rules in the interest of setting forth agency procedure with respect to conducting such investigations. However, text from the existing rules was inadvertently omitted in the publication of the amendments. This correction serves as a clarification of the inadvertent omissions.

DATES: *Effective:* February 2, 1998.

FOR FURTHER INFORMATION CONTACT: Ethiopis Tafara, Senior International Counsel, Division of Enforcement, US Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st Street, NW, Washington, DC 20581. Telephone (202) 418–5362.

SUPPLEMENTARY INFORMATION: The Commission is correcting inadvertent omissions in the publication of the final rules amending §§ 11.1 and 11.2(a) of the Commission's Rules. The amendments expanded the scope of 17 CFR Part 11 and authorized formally the Director of the Division of Enforcement to conduct investigations in assistance of foreign futures authorities. As the Supplementary Information accompanying the amendments made clear, no other change in §§ 11.1 and 11.2(a) of the Commission's Rules was being made.[1] However, certain existing language in §§ 11.1 and 11.2(a) of the Commission's Rules relating to agency practice was not republished at that time. The omitted language serves as an elaboration of the scope of 17 CFR Part 11 as set forth in the first sentence of §11.1 and of the authority delegated to the Director of the Division of Enforcement as recited in the first sentence of §11.2(a). Part of the omitted language also describes agency practice with respect to certain investigatory activities conducted by the Director of

[1] *See* 62 FR 17702.

the Division of Trading and Markets and the Chief Economist and Director of the Division of Economic Analysis. So as to avoid any confusion of the public, and to ensure its inclusion in this year's edition of the Code of Federal Regulations, this correction sets out the language relating to agency procedure that was not included with the original amendments. Consequently, the Commission is not seeking public comment. Similarly, the Commission finds good cause to make this correction clarifying the omissions effective immediately.

In final rule, FR Doc. 97–9399, published on April 11, 1997 (62 FR 17702) make the following corrections:

PART 11—[CORRECTED]

1. On page 17702, in the second column, § 11.1 is corrected to read as follows:

§ 11.1 Scope and applicability of rules.

The rules of this part apply to investigatory proceedings conducted by the Commission or its staff pursuant to Sections 6(c) and 8 and 12(f) of the Commodity Exchange Act, as amended, 7 U.S.C. 9 and 15 and 12 and 16(f) (Supp. IV, 1974), to determine whether there have been violations of that Act, or the rules, regulations or orders adopted thereunder, or, in accordance with the provisions of Section 12(f) of the Act, whether there have been violations of the laws, rules or regulations relating to futures or options matters administered or enforced by a foreign futures authority, or whether an application for designation or registration under the Act should be denied. Except as otherwise specified herein, the rules will apply to the conduct of investigation whether or not the Commission has authorized the use of subpoenas in the particular matter to compel the production of evidence.

2. On page 17702, in the third column, § 11.2, paragraph (a) is corrected to read as follows:

§ 11.2 Authority to conduct investigations.

* * * * *

(a) The Director of the Division of Enforcement and members of the Commission staff acting pursuant to his authority and under his direction may conduct such investigations as he deems appropriate to determine whether any persons have violated, are violating, or are about to violate the provisions of the Commodity Exchange Act, as amended, or the rules, regulations or orders adopted by the Commission pursuant to that Act, or, in accordance with the provisions of Section 12(f) of the Act, whether any persons have violated, are violating or are about to violate the laws, rules or regulations relating to futures or options matters administered or enforced by a foreign futures authority, or whether an applicant for registration or designation meets the requisite statutory criteria. For this purpose, the Director may obtain evidence through voluntary statements and submissions, through exercise of inspection powers over boards of trade, reporting traders, and persons required by law to register with the Commission, or when authorized by order of the Commission, through the issuance of subpoenas. The Director shall report to the Commission the results of his investigations and recommend to the Commission such enforcement action as he deems appropriate. In particular matters the Director of the Division of Trading and Markets and the Chief Economist and Director of the Division of Economic Analysis, and members of their staffs acting within the scope of their respective responsibilities, are also authorized to investigate, report and recommend to the Commission in accordance with these rules.

* * * * *

Issued in Washington, DC on January 27, 1998, by the Commission.

Jean A. Webb,

Secretary of the Commission.

[FR Doc. 98–2470 Filed 1–30–98; 8:45 am]

BILLING CODE 6351–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 54, 312, 314, 320, 330, 601, 807, 812, 814, and 860

[Docket No. 93N–0445]

Financial Disclosure by Clinical Investigators

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is issuing regulations requiring the sponsor of any drug, including a biological product, or device marketing application (applicant), to submit certain information concerning the compensation to, and financial interests of, any clinical investigator conducting certain clinical studies. This requirement will apply to any covered clinical study of a drug or device submitted in a marketing application that the applicant or FDA relies on to establish that the product is effective, including studies that show equivalence to an effective product, or that make a significant contribution to the demonstration of safety. This final rule requires applicants to certify to the absence of certain financial interests of clinical investigators and/or disclose those financial interests, as required, when covered clinical studies are submitted to FDA in support of product marketing. This regulation is intended to ensure that financial interests and arrangements of clinical investigators that could affect reliability of data submitted to FDA in support of product marketing are identified and disclosed by the sponsor of any drug, biological product, or device marketing application. If the applicant does not include certification or disclosure, or both, if required, or does not certify that it was not possible to obtain the information, the agency may refuse to file the application. FDA intends to propose to extend these requirements to submissions for marketing approval related to human foods, animal foods, and animal drugs in a subsequent issue of the **Federal Register**.

DATES: This regulation becomes effective on February 2, 1999. Submit written comments on the information collection requirements by April 3, 1998.

ADDRESSES: Submit written comments on the information collection requirements to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Mary C. Gross, Office of External Affairs, Food and Drug Administration (HF–60), 5600 Fishers Lane, Rockville, MD 20857, 301–827–3440, FAX 301–594–0113.

SUPPLEMENTARY INFORMATION:

I. Background

In the **Federal Register** of September 22, 1994 (59 FR 48708), FDA published a proposed regulation to help ensure that financial interests and arrangements of clinical investigators that could affect reliability of data submitted to FDA in support of product marketing are identified and disclosed by the sponsor of any drug, biological product or device marketing application (applicant). In this document, FDA proposed to require disclosure by applicants of the following types of financial interests and arrangements: Compensation made to the clinical investigator in which the value of the compensation could be affected by the